Cambridge-based BioTech CellCentric has appointed Celia Economides as its new chief financial officer.
The news comes shortly after the University of Camridge spinout announced that it had raised £90m in Series C financing to support its oral treatment for multiple myeloma.
The investment is supporting the advancement of the Cambridge company’s oral treatment for multiple myeloma, inobrodib.
Despite significant recent progress in treating multiple myeloma, the majority of patients still succumb to the disease.
Economides is combining the role of CFO and chief business officer, and brings over two decades of strategic leadership experience across BioTech finance, corporate development and capital markets.
She will oversee financial strategy, business development and investor relations as CellCentric continues to expand its global footprint, shortly after the opening of its US headquarters in the Boston area last month.
BGF pledges £300m to female-powered firms as part of £3bn plan
Economides previously held senior roles at several listed companies in the industry and was most recently interim CEO and CFO of Gritstone bio, Inc.
“We are thrilled to welcome Celia to CellCentric,” said Will West, CEO of CellCentric. “Her proven leadership in building and financing biotech companies, coupled with her deep understanding of the US market will be instrumental as we advance inobrodib towards registration.
“Our global footprint is expanding rapidly to meet the needs of our next phase of progress, with the goal of improving the lives of people with multiple myeloma.”
Economides added: “I am honoured to join CellCentric at such an exciting inflection point. Inobrodib is truly a compelling potential oral first-in-class treatment for multiple myeloma.
“I look forward to partnering with Will, the board, our investors, and the CellCentric team to shape the next phase of growth, maximise value and ultimately bring a much-needed treatment to patients.”